Effective Management of Prostate Cancer Conclusion

For High-Definition, Click

In this segment, Raoul Concepcion, MD, wraps up the discussion by noting that conversations often provide urologists with the opportunity to stay involved and provide new points of view to their peers. In closing, Daniel R. Saltzstein, MD, Bryan Mehlhaff, MD, and Steve Dobbs, FACHE, each provide their opinions on key areas of interest in prostate cancer.

Saltzstein notes that a few different areas of prostate cancer are in need of further development, such as biopsying, surveillance, radiation, surgery, and androgen deprivation therapy. With all the recent advances and new treatments approved, it's an exciting time in prostate cancer, Mehlhaff points out. However, he adds, finding a cure for the disease should remain a goal of research. In terms of reimbursement and purchasing costs, Dobbs stresses that communication and trust between physicians is an important factor.

Related Videos
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Vivek Subbiah, MD